Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The current state of immunotherapy for gliomas: an eye toward the future.

Fecci PE, Sampson JH.

J Neurosurg. 2019 Sep 1;131(3):657-666. doi: 10.3171/2019.5.JNS181762. Review.

PMID:
31473668
2.

The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Paff M, Alexandru-Abrams D, Hsu FP, Bota DA.

Hum Vaccin Immunother. 2014;10(11):3322-31. doi: 10.4161/21645515.2014.983002. Review.

3.

Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.

Choi BD, Curry WT, Carter BS, Maus MV.

Neurosurg Focus. 2018 Jun;44(6):E13. doi: 10.3171/2018.2.FOCUS17788. Review.

PMID:
29852773
4.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

5.

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Seledtsov VI, Goncharov AG, Seledtsova GV.

Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814. Review.

6.

Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.

Wang JY, Bettegowda C.

J Neurooncol. 2015 Jul;123(3):373-83. doi: 10.1007/s11060-015-1730-4. Epub 2015 Feb 21. Review.

PMID:
25697584
7.

Therapeutic gene modified cell based cancer vaccines.

Kozłowska A, Mackiewicz J, Mackiewicz A.

Gene. 2013 Aug 10;525(2):200-7. doi: 10.1016/j.gene.2013.03.056. Epub 2013 Apr 6. Review.

PMID:
23566846
8.

Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.

Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT Jr.

J Immunother. 2012 Jun;35(5):385-9. doi: 10.1097/CJI.0b013e3182562d59.

9.

[Immunotherapy in brain tumors].

De Carli E, Delion M, Rousseau A.

Ann Pathol. 2017 Feb;37(1):117-126. doi: 10.1016/j.annpat.2016.12.001. Epub 2017 Jan 19. Review. French.

PMID:
28111040
10.

Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.

Ren PP, Li M, Li TF, Han SY.

Curr Pharm Des. 2017;23(14):2113-2116. doi: 10.2174/1381612823666170316125402. Review.

11.

Cellular immunotherapy for malignant gliomas.

Lin Y, Okada H.

Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29. Review.

12.

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE 2nd, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH.

PLoS One. 2014 Apr 10;9(4):e94281. doi: 10.1371/journal.pone.0094281. eCollection 2014.

13.

The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.

Maxwell R, Luksik AS, Garzon-Muvdi T, Lim M.

Curr Neurol Neurosci Rep. 2017 Jun;17(6):50. doi: 10.1007/s11910-017-0754-x. Review.

PMID:
28488122
14.

Perspectives for immunotherapy in glioblastoma treatment.

Finocchiaro G, Pellegatta S.

Curr Opin Oncol. 2014 Nov;26(6):608-14. doi: 10.1097/CCO.0000000000000135. Review.

PMID:
25210870
15.

Novel mechanisms and approaches in immunotherapy for brain tumors.

Finocchiaro G, Pellegatta S.

Discov Med. 2015 Jul-Aug;20(108):7-15. Review.

16.

DCVax®-L--developed by Northwest Biotherapeutics.

Polyzoidis S, Ashkan K.

Hum Vaccin Immunother. 2014;10(11):3139-45. doi: 10.4161/hv.29276. Review. Erratum in: Hum Vaccin Immunother. 2015;11(7):1881.

17.

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.

Jan CI, Tsai WC, Harn HJ, Shyu WC, Liu MC, Lu HM, Chiu SC, Cho DY.

Front Immunol. 2018 May 29;9:727. doi: 10.3389/fimmu.2018.00727. eCollection 2018.

18.

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.

Hum Gene Ther. 2012 Oct;23(10):1043-53. doi: 10.1089/hum.2012.041. Epub 2012 Sep 24.

19.

Targeting EGFRvIII for glioblastoma multiforme.

Yang J, Yan J, Liu B.

Cancer Lett. 2017 Sep 10;403:224-230. doi: 10.1016/j.canlet.2017.06.024. Epub 2017 Jun 23. Review.

PMID:
28649003
20.

Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.

Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H.

Biomed Pharmacother. 2019 May;113:108734. doi: 10.1016/j.biopha.2019.108734. Epub 2019 Mar 5.

Supplemental Content

Support Center